Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 16, Art. 74 (pp. 809-825)    |    2015       

»

Evaluation of the dexamethasone biodegradable implant efficacy in treatment of the retinal vein occlusion induced by photodynamic therapy on a rabbit model.

Yu. A. Belyy1, A.A. Temnov2, S.V. Novikov3 , S.V. Кolesnik4, A.I. Kolesnik4

1The Kaluga branch of the S.N. Fyodorov Federal State Institution
2N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department, Moscow
3The Research Experimental Production of Eye Microsurgery, Moscow
4The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow

Brief summary

Thrombosis of central retinal vein (CRV) occurs acutely, usually sided with the formation of thrombotic masses in the lumen of the trunk and branches of CRV. It is characterized by severe disturbances of visual functions, until the development of blindness. One of the major reasons for the decline of a macular edema (ME) due to increased permeability of the blood-retinal barrier. One of the effective methods for treating MO is the drug administration into the vitreous using biodegradable implants. However, the question remains the development and improvement of drug delivery to the posterior segment of the structures of the eyeball with effective bioresorbable devices. Objective: To evaluate the performance of the implant, saturated with dexamethasone, as a drug container on а model of photoinduced thrombosis of central retinal vein in rabbits. The implant is multilayered tubular device length of 4.0 mm and a diameter of 0.3 mm. Each layer has a thickness of 10 microns. The implant has a rich dexamethasone 8 layers, that alternate with 7 unsaturated layers. The effectiveness of the implant containing dexamethasone was evaluated on the developed photo-induced pathophysiological model of thrombosis of CRV branches in 10 adult rabbits. Animals were divided into two equal groups. The rabbits in Group 1 were injected into vitreous cavity of the implant with dexamethasone at a dose of 300 mg; in the 2nd - did intravitreal injection of 0.1 ml of 0.4% dexamethasone (400 mg). Within 14 days the eyes of rabbits was examined by ophthalmoscopy, photographic images of the eye, optical coherence tomography and ERG. Dynamics of a clinical symptoms reduction of thrombosis after the implant administration was more significant than after a single dexamethasone injection.


Key words

thrombosis, macular edema, implant, dexamethasone, pathophysiology experimental model

Reference list

1. Abdylaeva E.A., Amirov A.N., Beriya Djordjikiya E.P., Korobicin A.N. Kompleksnoe lechenie okkluzii ven setchatki // Kazanskii med. jyrn. 2012. T. 93. № 6. S. 954–956.


2. Belii U. A. Tereshenko, A. V., Parshin, V. S., Teshin, V. V. Yltrazvykovie kriterii v diagnostike i ocenke effektivnosti hiryrgicheskogo lecheniya polnogo tromboza centralnoi veni setchatki. Obzor //Refrakcionnaya hiryrgiya i oftalmologiya. – 2008. – T. 8. – №. 4. – S. 4.


3. Belii U.A., Tereshenko A.V., Shackih A.V., Velibekova D.S., Shaylov V.V., Solovev D.K., Erohina E.V. Eksperimentalnoe obosnovanie fotoindycirovannoi modeli tromboza vetvi CVS // Oftalmohiryrgiya.- 2011.- №4.- S. 26-28.


4. Velibekova D.S. Eksperimentalnaya model fotoindycirovannogo tromboza vetvi centralnoi veni setchatki: Dis. …kand. med. nayk.- M., 2012.- 105s.


5. Kiseleva T. N., Polynin G. S., Bydzinskaya M. V. i soavt. Korrekciya narysheniya gemodinamiki pri okkluzii retinalnih ven // Refr. hir. i oftalmol. 2007. T. 7. № 4. S. 36–39.


6. Mihailichenko V. U. Rol VEGF v angiogeneze pri norme i patologii / V. U. Mihailichenko // Novoytvorennya. — 2010. — № 5. — S. 174–181.


7. Mihailova M. A. Pluhova, A. A., Balackaya, N. V., Bydzinskaya, M. V. Osobennosti razvitiya okkluzionnih porajenii sosydov setchatki i zritelnogo nerva na fone serdechno-sosydistih zabolevanii // Prakticheskaya medicina. – 2012. – T. 2. – №. 59.


8. Mihailova M. A., Sizova M. V., Shelankova A. V. Patogenez retinalnih venoznih okkluzii // Vestnik oftalmologii. – 2014.- №2.- S. 88-92.


9. Moshetova L. K. i dr. Rol antikoagylyantov v lechenii ostroi sosydistoi patologii setchatki i zritelnogo nerva // Klin. oftalmol. – 2005. – T. 6. – S. 93-98.


10. Tankovskii V.E. Trombozi ven setchatki. M. 2000. 262 s.


11. Tylceva S. N. Trombofiliya kak faktor riska razvitiya trombozov centralnoi veni setchatki y lic molodogo vozrasta //Oftalmologicheskie vedomosti. – 2008. – S. 46.


12. Tylceva S.N., Astahov U.S. Okkluzii ven setchatki (etiologiya, patogenez, klinika, diagnostika, lechenie). SPb.: «Izdatelstvo N-L». 2010. 112 s.


13. Tylceva S. N., Nechiporenko P. A., Titarenko A. I. Ispolzovanie intravitrealnogo implantata «Ozyrdeks» v terapii postokkluzionnogo makylyarnogo otyoka //Oftalmologicheskie vedomosti. – 2014. – T. 7. – №. 3. – S. 5-16.


14. Zaharov V. D., Kashtan O. V., Osokin I. G. Lazernoe i hiryrgicheskoe lechenie ishodov trombozov retinalnih ven //Sovremennie tehnologii v medicine. – 2012. – №. 1.


15. Alkin Z. et al. Quantitative Analysis of Retinal Structures Using Spectral Domain Optical Coherence Tomography in Normal Rabbits //Current eye research. – 2013. – T. 38. – №. 2. – S. 299-304.


16. Boyer D.S., Faber D., Gupta S., et al; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients // Retina.- 2011.- Vol. 31(5).- P.915-923.


17. Campochiaro P. A. et al. Pro-permeability Factors after Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study //American journal of ophthalmology. – 2015.


18. Capone A., Singer M.A. Dodwell D.G. et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vien occlusion (Shasta study) // Retina. 2014. Vol. 34. № 2. P. 342–351.


19. Haller J.A., Bandello F., Belford R. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion // Ophthalmology. 2011. Vol. 118. № 12. P. 2453–2460.


20. Matsushima M., Yamada H., Yamamoto C.et al. Expression of basic fibroblast growth factor and fibroblast growth factor receptor 1 in the experimental retinal vein occlusion model // Nippon Ganka Gakkai Zasshi. — 1997. — Vol. 101. — N. 7. — P. 564–570.


21. Querques G. et al. Changes in Macular Function after Ozurdex for Retinal Vein Occlusion // Optometry & Vision Science. – 2014. – T. 91. – №. 7. – S. 760-768.


22. Scholl S., Augustin A., Loewenstein A., Rizzo S., Kupperman B. General


pathophysiology of macular edema // Eur. J. Ophthalmol.- 2011.- Vol. - 21, Suppl. 6.- P.10—19.


23.Yoshimura T., Sonoda K.H., Sugahara M., Mochizuki Y., Enaida H., Oshima Y., Ueno A., Hata Y., Yoshida H., Ishibashi T. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases // PLoS One.- 2009.- Vol. 4.- P.12-19.